Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The January 2004 monograph topics are risperidone long-acting injection; efalizumab; epinastine HCL ophthalmic solution; prussian blue; and bevacizumab. The DUE is on polonosetron.
Get full access to this article
View all access options for this article.
References
1.
Crestor [prescribing information].AstraZeneca Pharmaceuticals LP; August 2003.
2.
HanefeldM.Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.Int J Clin Pract.2001; 55: 399–405.
3.
NezasaK.Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat [abstract].Atherosclerosis.2000; 151: 39.
4.
McTaggartF.Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.Am J Cardiol.2001; 87(suppl): 28B–32B.
5.
SmithG.Pharmacological properties of ZS4522 — a new HMG-CoA reductase inhibitor [abstract].Atherosclerosis.2000; 151: 39.
6.
StalkerT.J.A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid.Br J Pharmacol.2001; 133: 406–12.
7.
WarwickM.J.Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract].Atherosclerosis.2000; 151: 39.
8.
MartinP.D.Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.Br J Clin Pharmacol.2002; 54: 472–7.
9.
MartinP.D.No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor.J Clin Pharmacol.2002; 42: 1116–21.
10.
SimonsonS.G.Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects.Clin Pharmacol Ther.2001; 69(2, suppl): P86.
11.
SimonsonS.G.Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.Eur J Clin Pharmacol.2003; 58: 669–75.
12.
OlssonA.G.Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.Am J Cardiol.2001; 88: 504–8.
13.
OlssonA.G.Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolemia [abstract].Atherosclerosis.2000; 151: 39.
14.
OlssonA.G.ZD4522 — a new HMG-CoA reductase inhibitor — causes rapid and profound reductions in plasma LDL-C levels in patients with primary hypercholesterolaemia.Eur Heart J.2000; 21(suppl): 156.
15.
PaolettiR.ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines [abstract].J Am Coll Cardiol.2001; 37(2, suppl): 291A.
16.
PaolettiR.Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesteraemic patients: A randomized, double-blind study.J Cardiovasc Risk.2001; 8: 383–90.
17.
BrownW.V.Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin [abstract].Eur Heart J.2001; 22(suppl): 270.
18.
BrownW.V.Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial.Am Heart J.2002; 144: 1036–43.
19.
DavidsonM.H.ZD4522 is superior to atorvastatin in decreasing low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia [abstract].J Am Coll Cardiol.2001; 37(2, suppl): 292A.
20.
DavidsonM.Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.Am J Cardiol.2002; 89: 268–75.
21.
OlssonA.Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin [abstract].Eur Heart J.2001; 22(suppl): 253.
22.
OlssonA.G.Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.Am Heart J.2002; 144: 1044–51.
23.
JonesP.H., Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).Am J Cardiol.2003; 92: 152–60.
24.
SchneckD.W.Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.Am J Cardiol.2003; 91: 33–41.
25.
SteinE.A.ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterogenous familial hypercholesterolemia [abstract].J Am Coll Cardiol.2001; 37(2, suppl): 291A.
26.
SteinE.A.ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia [abstract].J Am Coll Cardiol.2001; 37(2, suppl): 292A.
27.
HunninghakeD.B.Treatment of hypertriglyceridemic patients with rosuvastatin [abstract 574-P]. 61st Scientific Sessions of the American Diabetes Association; June 22–26, 2001; Philadelphia, PA.
28.
HunninghakeD.B.Rosuvastatin markedly improved the atherogenic lipid profile in hypertriglyceridemic patients [abstract].Eur Heart J.2001; 22(suppl): 270.
29.
MaraisD.Effect of rosuvastatin on LDL-cholesterol, mevalonic acid and other lipid measurements in patients with homozygous familial hypercholesterolaemia [abstract].Atheroscler Suppl.2002; 3(2): 159.
30.
DurringtonP.Rosuvastatin alone and in combination with fenofibrate in hyperlipidemic patients with type 2 diabetes [abstract].Diabetologia.2001; 44(Suppl 1): A165.
31.
DurringtonP.Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: Results at 24 weeks.Circulation.2001; 104(17, suppl): II–177.
32.
CapuzziD.M.Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.Am J Cardiol.2003; 91: 1304–10.
33.
Lipitor [prescribing information].Pfizer Pharmaceuticals; November 2002.
34.
Zocor [prescribing information].Merck & Co., Inc.; April 2003.
35.
Pravachol [prescribing information].Bristol-Myers Squibb Company; March 2003.
36.
Lescol and Lescol XL [prescribing information]. Novartis Pharmaceuticals Corporation; May 2003.
37.
Mevacor [prescribing information].Merck & Co., Inc.; June 2002.
38.
MartinP.D.An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.Clin Ther.2003; 25: 459–71.
39.
CooperK.J.Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.Br J Clin Pharmacol.2003; 55: 94–9.
40.
CooperK.J.The effect of erythromycin on the pharmacokinetics of rosuvastatin.Eur J Clin Pharmacol.2003; 59: 51–6.
41.
CooperK.J.Effect of itraconazole on the pharmacokinetics of rosuvastatin.Clin Pharmacol Ther.2003; 73: 322–9.
42.
KempJ.V.Coadministration of rosuvastatin does not alter the pharmacokinetics of digoxin [abstract].Pharmacotherapy.2001; 21: 1255.
43.
MartinP.D.No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.J Clin Pharmacol.2002; 42: 1352–7.
